• Tonix highlighted early commercial traction for fibromyalgia drug TONMYA, launched Nov. 17, 2025; net sales totaled $3.7 million in 1Q26.
• Run-rate metrics through early May showed more than 2,700 unique prescribers, about 5,618 unique patients, about 11,016 prescriptions.
• Cash and cash equivalents were about $185.5 million as of March 31, 2026; no debt; cash runway expected into early Q2 2027.
• Pipeline priorities include TNX-4800 Lyme disease prevention program with adaptive Phase 2 field study planned in 1H27, pending FDA agreement.
• Additional clinical plans include Phase 2 work for TNX-102 SL in major depressive disorder and acute stress disorder in 2026, Phase 2 transplant rejection study for TNX-1500 in mid-2026, Phase 2 Prader-Willi study for TNX-2900 in 1Q27.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on May 14, 2026, and is solely responsible for the information contained therein.